BIOMAT Database Logo BIOMAT Database Logo

[Cisplatin etoposide versus cisplatin/etoposide/ifosfamide combination chemotherapy in small-cell lung cancer: a multicenter randomized controlled study. Hokkaido Study Group of Treatment for Small-Cell Lung Cancer]. 1991

H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
First Dept. of Medicine, Hokkaido University.

Ninety-two patients with small-cell lung cancer (SCLC) were randomized to receive cisplatin (80 mg/m2, day 1)/etoposide (100 mg/m2, day 1, 3, 5) (PE) or cisplatin (80 mg/m2, day 1)/etoposide (100 mg/m2 1, 3, 5)/ifosfamide (2 g/m2, day 1, 2, 3) (PEI) combination chemotherapy. After 2 courses of chemotherapy, patients with limited disease (LD) received chest irradiation with 40-50 Gr. Of the 89 patients evaluable, the overall response rate was 77.8% in PE therapy, and 73.7% in PEI therapy (NS). The complete response rate (CR) of PE v PEI was 13.9% v 21.2% for all patients (NS), 22.2% v 30.4% for LD. Median survival times of PE v PEI for all patients were 55 weeks v 56 weeks (NS). The 2-year survival rate of PE v PEI was 15.4% v 16.5% for all patients (NS). There was no difference of the duration of response in cases with CR or PR between PE and PEI therapy. Leucopenia occurred more often after PEI than after PE therapy (p less than 0.01). These results suggest that PEI is not superior to PE chemotherapy in SCLC.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
December 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.
June 1994, Seminars in oncology,
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
[Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer].
June 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine.
April 1997, Journal of chemotherapy (Florence, Italy),
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.
January 2002, Annals of oncology : official journal of the European Society for Medical Oncology,
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
[A combination chemotherapy of cisplatin and etoposide in small cell lung cancer].
March 1988, Nihon Gan Chiryo Gakkai shi,
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
[A combination chemotherapy of cisplatin and etoposide in small cell lung cancer].
October 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
Paclitaxel/etoposide/cisplatin versus etoposide/cisplatin for small-cell lung cancer.
February 2000, Clinical lung cancer,
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
July 1996, Annals of oncology : official journal of the European Society for Medical Oncology,
H Miyamoto, and Y Kawakami, and T Arimoto, and M Asakawa, and A Suzuki, and T Fujikane, and S Onodera, and T Nakabayashi, and S Yasuda, and T Shimizu
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
April 2001, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!